0001193125-24-113904.txt : 20240425 0001193125-24-113904.hdr.sgml : 20240425 20240425161134 ACCESSION NUMBER: 0001193125-24-113904 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240425 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vincerx Pharma, Inc. CENTRAL INDEX KEY: 0001796129 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 833197402 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39244 FILM NUMBER: 24876399 BUSINESS ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-800-6676 MAIL ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: Vincera Pharma, Inc. DATE OF NAME CHANGE: 20201223 FORMER COMPANY: FORMER CONFORMED NAME: LifeSci Acquisition Corp. DATE OF NAME CHANGE: 20191206 8-K 1 d816940d8k.htm 8-K 8-K
false 0001796129 0001796129 2024-04-25 2024-04-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2024

 

 

Vincerx Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39244   83-3197402
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

260 Sheridan Avenue, Suite 400

Palo Alto, California

   94306
(Address of principal executive offices)   (Zip Code)

(650) 800-6676

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.3e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   VINC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

Vincerx Pharma, Inc. (the “Company”) had cash and cash equivalents of approximately $5.1 million as of March 31, 2024 and $6.6 million as of April 15, 2024. From April 9, 2024 through April 12, 2024, the Company issued an aggregate of 2,120,849 shares of its common stock pursuant to the Company’s Sales Agreement, dated March 29, 2024 (the “ATM Agreement”), with Leerink Partners (the “Sales Agent”), providing for sale of shares of its common stock having an aggregate offering price of up to $50.0 million in at-the-market offerings, resulting in net proceeds of approximately $2.4 million and after paying commission to the Sales Agent of approximately $0.1 million. As of April 15, 2024, approximately $47.5 million remained available under the ATM Agreement.

The Company has not completed preparation of its financial statements for the quarter ended March 31, 2024. The preliminary, unaudited cash and cash equivalents provided in Item 2.02 of this Current Report on Form 8-K is based on current expectations and is subject to adjustment. Actual results may differ materially from those disclosed in this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01

Other Events.

On April 25, 2024, the Company announced that it has commenced an underwritten public offering of its common stock and accompanying common warrants to purchase common stock, and to certain investors, pre-funded warrants to purchase common stock and accompanying common stock warrants to purchase common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.   

Description

99.1    Press Release dated April 25, 2024.
104    Cover Page Interactive Date File (embedded within the Inline XBRL document).

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 25, 2024

 

VINCERX PHARMA, INC.
By:  

/s/ Alexander A. Seelenberger

Name:   Alexander A. Seelenberger
Title:   Chief Financial Officer
 EX-99.1 2 d816940dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

PALO ALTO, CA, April 25, 2024 — Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offering will be offered by Vincerx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners is acting as the sole bookrunning manager for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-262239) that was declared effective by the Securities and Exchange Commission (the “SEC”) on January 28, 2022. The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. Vincerx’s diverse pipeline consists of the next-generation antibody-drug conjugate, VIP943, in Phase 1; small molecule-drug conjugate, VIP236, in Phase 1; preclinical antibody-drug conjugate, VIP924; CDK9 inhibitor, enitociclib, in an NIH-sponsored Phase 1; and VersAptx™, its versatile and adaptable, next-generation bioconjugation platform.

Vincerx is based in Palo Alto, California, and has a research facility in Monheim, Germany.

LOGO

 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as those, among others, relating to Vincerx’s expectations regarding the completion and timing of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering. More information about the risks and uncertainties faced by Vincerx is contained in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering and are detailed from time to time in Vincerx’s periodic reports filed with the SEC, including its most recent Annual Report on Form 10-K. Vincerx disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Gabriela Jairala

Vincerx Pharma, Inc.

gabriela.jairala@vincerx.com

Totyana Simien

Inizio Evoke Comms

totyana.simien@inizioevoke.com

 EX-101.SCH 3 vinc-20240425.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 vinc-20240425_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 vinc-20240425_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g816940dsp5.jpg GRAPHIC begin 644 g816940dsp5.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 B17AI9@ 34T *@ @ 0$2 , M ! $ #_VP!# (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8' M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# S_P 1" ! 'H# 2( A$! Q$!_\0 'P 04! 0$! M 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%! 0 %] 0(# M 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 M $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)! M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]_**** "BBB@ HHHH *** M* "BN?\ BO>RV7PWUK[/?+I=Y<6CVMI=LVU;>XE'EPL6_AQ(R3_A%?'6G-]CNH+\>3%=RH=I96/"N3U1L88D#=V]'"97B,50J5 ML.N;V=N9+623O:5M^71J_3J>)CN(,%@L92P>+ER.JGRMZ1;35XWV4M4TGOK; M8^BJ* FP<[3,_S28ZA5'S,?9037E5JU.E!U*LE& M*W;=DO5L]J4DE=FU5;5]9M/#^FS7E]=6]G:6Z[I)II!''&/4D\"OG?Q=^WA< M>)=1;2OAWX:OM.K?5,BHRQ-1NUXIJ"?G*V MOI%-OH>=7S2E"+DGHMVW:*]6]#ZO\">/K'XC:7-?Z8MP^GI.T$5Q)'L6ZV\, MR \E0V5R0.5/I6Y7RS^RG\:]<_:\^)=CXFTG2;SP7\&/"*26GA^WN%$$_BB\ M*&,2E>GD0Q^9M09&]@269"L?U-7VF(R_$8+EH8QIU4ES6V4NJW>W:[:V;NF5 MEN80QE'V]/X;Z.UN9=TM[-WM?=*ZT:845\;_ /!3G]L/Q]^R=^TG^R[:>'=2 ML;3P7\2/'"^%_%,,]BDS3+/);+#LD;YHR T_W>O'I1^P'^V!\0/VE_V^OVI? M"^L:A8S?#_X3ZS9:'H%M%9QQRQS,)Q/NE W/AH/XB<;^U^ M+^O^./VM?C9X?U+XJ^"?&6E^&;NTCT_PSI-D8=2\)*_F[DO)-H\QGVC!R?N- MTSBKGQ<_X*A?L^_ 7XCZEX0\9?%GP?X=\3:.R)>Z=>712:U+HLBAACC*.K?1 MA0*Q[U16;X-\9Z3\1/"FGZ[H.IV.M:+JUNEU97UE.L]O=Q.,JZ.I*LI!R"#7 MD_@/_@HY\"?BA\:Y?ASX?^*W@O5_&D4KVXTNVU!6DFE3.^.-ON2.NULJC,PV MGC@T >U45S_Q2^*_AGX(^ ]1\4>,->TOPUX=TF/S;S4=1N5M[>!20!EF(&22 M !U)( !) KE?V;?VP_A?^V!H%[J?PS\<:!XRM=-E$-Y_9]QNEM&.2OF1MATW M8.TLH#8.,X- '3?&&WMKOX8:Y'>V=S?V36K"XAMO]?Y?\;1CNZKEE'@:'\1M/A0);:_9ZFFGZE:Q#A?-VS4DWNI+3=-:I^3FF3X?,(>RQ4%.#W M4DFG\FFOPTZ,\IT?PY-^RAX)U);+QIJFE^'9B(HM4\4W1N/LP XCL+-5W2N2 M>NU=P4;4/+'R;6=5\2^/M9>[\%_!7XB?$G4I9.-<\:S'0-.)&<2102,LLD7/ M"NZ^PQBOK?3?CC\/O'_QOUWX=Z7XHTNY^(?A2T6[U/3K9UDU#2895C*LQ*D) MN66,XZD..*^5_P!LWP7XPT[5+Q=3^ ?Q%^+_ (?4L8IM.^*=VL,H[!K&((RD M^BQL.V37U.$RO+LSQGUK.H?6*M[_ +QKD7I34J<6_-R;?6YY<^&Z\*,<'EC4 M(1V5TK>DIJ:7E[C:Z/H>8_%+QS\5O#6GRV?CGX]_"/X&Z1SYFA^#4^T:E"/^ MN5NIFR.F?.Y-?.-Q\6OA#X0\7+-X5\*^,OCSXZNI (M3\9.PL99AT9+&)FDN M ?[LTO?[M:6K?'BS\&:@UM8_L%ZE8W$9VHFKSZO?8^J20KFO1O@KXO\ VQ?C M?<1Z;\,?@OX)^ .BW8\N75X_"ZZ2T49X+%[D/))]8HRW\Z_7L+BL-@:'+3IJ M$;;*5.C#_P IN/5\-BE:"\K0370^H/^">? M[/\ \6/%_P 0(_BI\;M0FM=2L;1K;PQX6V+;PZ'%(IC,WV9 %A/E@QJN-Q4M MOY"U]H5Y+^Q]^R]_PS#\.9K34_$>K>-?&&N3"]\0>(M3F>6YU.XV[0%W,QCA MC7Y4C!PHR>K,3ZU7Y/G>8/&8N573E6D5%K/LLLRJEEU'Z MO2DYZW\W_GF@E>$ M_P#CTJ?D*B_X(#V8\7^%?VCOB22'_P"%C?&77;VW?'W[9'3R^?0-)(!]*]:_ MX+8?">Y^-7_!+/XRZ'8V=Q?WZ:*NI6L$$1DF>2TGBNE"*O);]SP!S7/?\$"_ MA+J'P>_X)4_#*SUBTO++6M5%_J]_%=0F*827%].Z[E8 @^7Y?45Y)Z70\B_X M)2?\IDOV\/\ L+:+_P"@W=>!?$CX;>'/'_\ P4B_X*2SZ]X?T/7)M%^&(O-. MDU"PBNFL)UT6(K+"74F-P0"&7!&!S7TQ_P $T/AIXB\!_P#!8#]MF\UK0]4T MNRU^\T.]TRYN;9XX=0@9;LB2%R-LB\X)4G!R#@@@>,:YX UX?\%!O^"DMY_8 M>M&SUKX6&'3IA8RF._D_L:-=D+;<2-NXVKDD\4 >^_\ !+2ZELO^#?OPK-#) M)#-#X$UIXY$8JR,)+T@@]00>A'2O"?\ @C7_ ,$TOAG^UY_P2[_9Y\6:W93Z M%XI\#^*;WQ);ZQH<-M:ZA?SVVJW/E1W,[1-))$-J_+N!&U<$8%?1_P#P2H^& MVM:K_P $-O!?A-M/N+'7M0\(:MIT=I>QM;2)-+->(@<. 5!++R1T.>E?'W_! M+K]M[XL?LW? ;X)_LQ^"_A#XJF^)VC^++JT\=KXC\/7,.GZ)I4VH7$TES'<+ M*H#+&ZD,X*GHH_0J7CE@6VO68 M.@SO7 SMP[_\ !Q9\&?%7Q9_8J\*WWA?P]JGB;_A! M_'FF^(]6L]-MS M.[GP_P##&;PO\"='TF!='\0:MH*M7_9 TGX1^!]/U6]\3_'+Q%9>%!+9VLDJV-D\J-;PYX&U\>(O!FHW MML_DW>F7B(6C6;:$8QY@) /+RR_W3C]$J!2W"BBB@04444 %%%% !1110 5Q M/QR^,:_!G1M)N?L=K>2:QJ(T^/[5J,=A;PGR)IR[S2 JHVPD =V917;5S_CS MX;V'Q#N]!DU#YX] U+^TXXBBO'._D30A7# \8F9N,'*KS0!@ZM\?K'2_V>[? MXB&PO%T^XT^WU'[+,5BFC2;9PQ)VC:'R3G& >:UOAA\5].^*XUZ32VBFM=$U M1M,%S%.DT5V5AAE+HRDC'[W;CKE35CXH_#RU^*W@/4/#]Y--;VNH!%D>(+N M5U?C<".=N.1T)IO@;X<6?P_EU]K!W5=?U)M3D38JI [0Q1;4"@?+B$'G)R33 M R_AM\;K/XD^.?%&APV-U:/XZ2)Y8@.=J3PSQ'/>//0BL#6O MVH8-'^/B>!_[':=VNK:S:>.^C-QNF@>82"V^^T*AZ:8:IYLB3-)(K$JC>:KN/+"C,K\)FO+R/46U:RU92@3Y&MH&@$8.W=L=';<,YYXQ1H!9\<_&^U\!_%WPC MX5NK&X9?%D=VRWXD58;-H50JK@\_O-Q (Z$8/44_X"_&FV^//@>77+2PNM.@ M2^N+-([@@NZQOA9..@=<,!V!JI\:_P!GG3?C?\U]J.IZ?(NGRV$4MDRK)!OG MMY_-4LIPX-NH!Z8=O6MCP5\+K;X?^'M8T_2[JXMUU2\N;U'"IFS>;H(QC&U. M-H(/3G-&@%#X0?&^S^+VI>([:WL;JQ;0;XV\33,&74+.91GG M]T?:NWKR3PM^Q[H?P_B5?#NL>)-%9M*M]*N)(;]I)+A8)1+'(2^[:P)E!";5 4(G?CI7K:C:H'7'<]Z0!1110!_]D! end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 25, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001796129
Document Type 8-K
Document Period End Date Apr. 25, 2024
Entity Registrant Name Vincerx Pharma, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39244
Entity Tax Identification Number 83-3197402
Entity Address, Address Line One 260 Sheridan Avenue
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94306
City Area Code (650)
Local Phone Number 800-6676
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol VINC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d816940d8k.htm vinc-20240425.xsd vinc-20240425_lab.xml vinc-20240425_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d816940d8k.htm": { "nsprefix": "vinc", "nsuri": "http://vincerx.com/20240425", "dts": { "inline": { "local": [ "d816940d8k.htm" ] }, "schema": { "local": [ "vinc-20240425.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "vinc-20240425_lab.xml" ] }, "presentationLink": { "local": [ "vinc-20240425_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-25_to_2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d816940d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-25_to_2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d816940d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vincerx.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-113904-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-113904-xbrl.zip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d816940d8k_htm.xml IDEA: XBRL DOCUMENT 0001796129 2024-04-25 2024-04-25 false 0001796129 8-K 2024-04-25 Vincerx Pharma, Inc. DE 001-39244 83-3197402 260 Sheridan Avenue Suite 400 Palo Alto CA 94306 (650) 800-6676 false false false false Common Stock, $0.0001 par value per share VINC NASDAQ true false